BioCentury | Jul 31, 2015
Financial News

Zogenix raises $85.5M in follow-on

...the U.S. and EU to treat Dravet. Zogenix gained ZX008 through its 2014 acquisition of Brabant Pharma...
BioCentury | Dec 22, 2014
Company News

Brabant Pharma, Zogenix deal

...Brabafen to treat Dravet syndrome, is expected in late 2016. Brabafen consists of low-dose fenfluramine. Brabant Pharma...
BioCentury | Jan 20, 2014
Clinical News

Brabafen regulatory update

...to start Phase III testing of Brabafen next half. The product consists of low-dose fenfluramine. Brabant Pharma...
Items per page:
1 - 3 of 3
BioCentury | Jul 31, 2015
Financial News

Zogenix raises $85.5M in follow-on

...the U.S. and EU to treat Dravet. Zogenix gained ZX008 through its 2014 acquisition of Brabant Pharma...
BioCentury | Dec 22, 2014
Company News

Brabant Pharma, Zogenix deal

...Brabafen to treat Dravet syndrome, is expected in late 2016. Brabafen consists of low-dose fenfluramine. Brabant Pharma...
BioCentury | Jan 20, 2014
Clinical News

Brabafen regulatory update

...to start Phase III testing of Brabafen next half. The product consists of low-dose fenfluramine. Brabant Pharma...
Items per page:
1 - 3 of 3